Evidence map›Paper›PMID 34830531›Full record

ArticleJournal of clinical medicine2021

Adjuvant Lineage-Negative Cell Therapy as a Potential Silencer of the Complement-Mediated Immune System in ALS Patients.

Anna Sobuś, Bartłomiej Baumert, Monika Gołąb-Janowska, Piotr Kulig, Edyta Paczkowska, Karolina Łuczkowska, Dorota Rogińska, Alicja Zawiślak, Sławomir Milczarek, Bogumiła Osękowska and 6 more

Open access · goldAbstract read
In one paragraph

Article in Journal of clinical medicine, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.2field-weighted citation impact, top 49% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 1 citations in OpenAlex.

  1. Article
  2. Amyotrophic Lateral Sclerosis: Advances and Prospects.Journal of clinical medicine · 2023
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors at 1 institution in 1 country.

Anna SobuśDepartment of General Pathology, Pomeranian Medical University, 70-111 Szczecin, Poland.
Bartłomiej BaumertDepartment of General Pathology, Pomeranian Medical University, 70-111 Szczecin, Poland.ORCID 0000-0001-9933-5844
Monika Gołąb-JanowskaDepartment of Neurology, Pomeranian Medical University, 71-252 Szczecin, Poland.
Piotr KuligDepartment of General Pathology, Pomeranian Medical University, 70-111 Szczecin, Poland.
Edyta PaczkowskaDepartment of General Pathology, Pomeranian Medical University, 70-111 Szczecin, Poland.ORCID 0000-0001-7052-9741
Karolina ŁuczkowskaDepartment of General Pathology, Pomeranian Medical University, 70-111 Szczecin, Poland.ORCID 0000-0003-4008-7473
Dorota RogińskaDepartment of General Pathology, Pomeranian Medical University, 70-111 Szczecin, Poland.ORCID 0000-0001-8884-837X
Alicja ZawiślakDepartment of General Pathology, Pomeranian Medical University, 70-111 Szczecin, Poland.ORCID 0000-0003-2036-2853
Sławomir MilczarekDepartment of General Pathology, Pomeranian Medical University, 70-111 Szczecin, Poland.ORCID 0000-0003-4445-6192
Bogumiła OsękowskaDepartment of General Pathology, Pomeranian Medical University, 70-111 Szczecin, Poland.
Wioletta PawlukowskaDepartment of Neurology, Pomeranian Medical University, 71-252 Szczecin, Poland.ORCID 0000-0002-4974-4292
Agnieszka MellerDepartment of Neurology, Pomeranian Medical University, 71-252 Szczecin, Poland.
Karolina Machowska-SempruchDepartment of Neurology, Pomeranian Medical University, 71-252 Szczecin, Poland.
Agnieszka WełnickaDepartment of Neurology, Pomeranian Medical University, 71-252 Szczecin, Poland.
Przemysław NowackiDepartment of Neurology, Pomeranian Medical University, 71-252 Szczecin, Poland.
Bogusław MachalińskiDepartment of General Pathology, Pomeranian Medical University, 70-111 Szczecin, Poland.
Pomeranian Medical University · PL

Funding

National Centre for Research and Development STRATEGMED1/ 234261/2NCBR/2014
6 · The paper itself

Abstract

ALS remains a fatal, neurodegenerative motor neuron disease. Numerous studies seem to confirm that innate immune system is involved in the pathophysiology of ALS. Hence, the assessment of the complement system and attempts to modify its activity remain the target of medical intervention in ALS. In the present study, three intrathecal administrations of autologous bone marrow-derived lineage-negative (Lin

Indexed as

amyotrophic lateral sclerosiscell therapycomplement systeminnate immunitylineage-negative cells

Identifiers

PMID34830531
PMCPMC8624979
OpenAlexW3214445654

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.